Kornimate/medical-research-clean huggingface dataset:
effects of acute ingestion of dark chocolate on endothelial function in hypertensive patients

Conditions: Hypertension

Summary: we aimed to identify clinical and vascular parameters of treated hypertensive patients who present beneficial effects of dark chocolate for one-week period on vascular function.

recent findings indicate an inverse relationship between cardiovascular disease and consumption of flavonoids. we aimed to identify clinical and vascular parameters of treated hypertensive patients who present beneficial effects of dark chocolate for one-week period on vascular function. twenty-one hypertensive patients in drug therapy, both genders, aged 40-65 years, were included in a prospective study with measurement of blood pressure, brachial flow-mediated dilatation (fmd), peripheral arterial tonometry (endopat) and central hemodynamic parameters by sphygmocor. after seven days of eating dark chocolate (70% cocoa) 75g/day, the clinical and vascular evaluation were repeated. patients were divided into two groups according to the response in fmd: responders (increase in fmd, n=12) and non-responders (no improvement in fmd, n=9).

Eligibility criteria:
inclusion criteria: * previous diagnosis of hypertension * use of one or two antihypertensive drugs * systolic blood pressure between 130 and 160 mmhg * diastolic blood pressure between 85 and 100 mmhg exclusion criteria: * secondary hypertension * diabetes mellitus * body mass index \> 35kg/m2 * chronic kidney disease * known coronary artery disease * previous stroke

Keywords: hypertension endothelial dysfunction vascular stiffness use of one or two antihypertensive drugs
a study of the relationship between drop in hemoglobin and sustained virological response in patients with chronic hepatitis c treated with copegus (ribavirin) and pegasys (peginterferon alfa-2a)

Conditions: Hepatitis C, Chronic

Summary: this open-label, multicenter, phase iv study will evaluate the relationship between the drop in hemoglobin levels and sustained virological response in patients with chronic hepatitis c genotype 1 treated with copegus (ribavirin) and pegasys (peginterferon alfa-2a). patients will receive copegus 1000 mg or 1200 mg orally daily and pegasys 180 mcg subcutaneously weekly. anticipated time on study treatment, depending on virological response, will be 48 or 72 weeks.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * chronic hepatitis c, genotype 1 * treatment-naïve or patients who relapsed or failed to respond to previous combination therapy with interferon and ribavirin * detectable hcv-rna * fertile males and females of child-bearing potential must agree to use two forms of contraception during treatment and for 6 months after treatment end exclusion criteria: * pregnant or breast-feeding women * male partners of pregnant women * history or evidence of a medical condition associated with chronic liver disease other than hcv * co-infection with active hepatitis a, hepatitis b and/or hiv virus * hepatocellular carcinoma * history or evidence of oesophageal varices or other conditions consistent with decompensated liver disease * anemia * any patient with increased baseline risk for anemia (e.g. thalassemia, spherocyctosis, history of gi bleeding) * history or evidence of significant cardiovascular disease * kidney disease * severe retinopathy * history of severe psychiatric disease, especially depression * therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) \</= 6 months prior to first dose of study drug
concomitant tracheostomy and lung resection

Conditions: Lung Cancer

Summary: this protocol has been designed to determine if tracheostomy performed immediately after lung operation (i.e. concomitant tracheotomy) could improve the postoperative outcome of high risk patients. we hypothesized that concomitant tracheotomy could reduce the length of mechanical ventilation and the number of respiratory complications.

background: respiratory failure after lung resection is a major complication. several studies suggest that low predictive postoperative pulmonary function is a predictive factor of mechanical ventilation (mv). in critically ill patients requiring mv, early tracheostomy may shorten the duration of mv and length of stay in intensive care. study objective: to determine whether concomitant tracheostomy (ct) would decrease the length of mv and improves outcome in patient with predictive postoperative forced expiratory volume in 1 second (fev1ppo) \< 50%. we call ct a tracheostomy performed immediately after the lung resection under the same general anesthesia. method: an open monocentric randomized controlled trial has been design. inclusion and exclusion criteria are mentioned below. fev1ppo will be calculated by the mean of the scintigraphic method for pneumonectomy and by the mean of the number of resected segments for lobectomy and segmentectomy. randomization will be made the day before the operation. the procedure will be an open surgical tracheostomy. a daily data base will be completed from randomization until discharge. the primary and secondary criteria are mentioned below.

Eligibility criteria:
inclusion criteria: * age between 18 and 79 years old * preoperative diagnosis of suspected lung cancer * patient considered operable according to the guidelines * 30% \< postoperative predicted fev1 \< 50% * informed consent obtained by patient exclusion criteria: * - age less than 18 and more than 79 * pregnant woman * preoperative tracheostomy * postoperative vocal cord paralysis * postoperative diaphragmatic paralysis (except for pneumonectomy) * neuromuscular disorders * previous pharyngeal or laryngeal surgery * anatomical deformity of the neck making risky a tracheostomy * consent refusal

Keywords: tracheostomy and thoracic surgery postoperative complications pulmonary surgical procedures respiratory failure
surface emgdi evaluate the efficacy of pulmonary rehabilitation in patients with copd: a multi center prospective study

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: pulmonary rehabilitation is recognized as a core component of the management of individuals with chronic obstructive respiratory disease, which has become first-line treatment besides drug therapy. however, in the current clinical evaluation system of pulmonary rehabilitation, there is still a lack of simple, objective index,which can be monitored at any time.neural respiratory drive , as an important physiological index, is closely related to the symptoms and the severity of the disease. it may be a sensitive indicator to evaluate the effectiveness of pulmonary rehabilitation. surface emgdi can accurately evaluate neural respiratory drive , its detection is non-invasive, simple and safety . in recent years, with the development of signal detection and analysis technology, emg recording is more stable, but as the related research samples were low, surface diaphragm emg has not yet the establishment of standardization. therefore, based on the previous work, the project was carried out in a multicenter randomized controlled study,in which the stable stage of copd patients were included in different ways of pulmonary rehabilitation training, a comprehensive clinical assessment will be conducted before and after training. compared with the traditional evaluation methods and standard esophageal diaphragmatic electromyography, surface emgdi detect the changes of neural respiratory drive in patients with copd,that can help to explore the application value of surface emgdi in the assessment of chronic obstructive pulmonary disease with pulmonary rehabilitation, to provide a basis for the promotion of the diaphragm and the optimization of pulmonary rehabilitation program.

the patients with copd will participate in a rehabilitation program for 52 weeks. participants in the proposed study will be randomly programmed into one of four intervention groups: 1. neither cycle training nor inspiratory muscle training. 2. cycle training program alone (performing on calibrated stationary cycle ergometer). 3. inspiratory muscle training alone (performing on threshold loading device). 4. combined cycle training and inspiratory muscle training(performing on calibrated stationary cycle ergometer and threshold loading device).

Eligibility criteria:
inclusion criteria: * patients aged over 40 years old. * patients with pulmonary function test of forced expiratory volume at one second(fev1)/forced vital capacity(fvc) \< 70%. * patients in a clinically stable state * patients who signed informed consent. * no participation in other pulmonary rehabilitation program within the previous 2 months. exclusion criteria: * patients with signs of an airway infection. * patients with metabolic disease and serious cardiovascular disease. * patients with multiple pulmonary bulla. * patients with poor compliance.

Keywords: surface emgdi pulmonary rehabilitation inspiratory muscle training exercise training
bovine carotid artery biologic graft and expanded polytetrafluoroethylene for permanent hemodialysis access

Conditions: End Stage Renal Disease; Hemolysis; Arteriovenous Graft

Summary: the investigators propose a randomized study to compare bovine carotid artery (bca) biologic grafts and expanded polytetrafluoroethylene grafts (eptfe) for permanent hemodialysis access.

arteriovenous grafts (avg) remain reliable substitutes for permanent hemodialysis access in scenarios that preclude the placement of arteriovenous fistulae. there is scarcity of evidence to support the current preference of synthetic conduits over biologic grafts in clinical practice. advances in the design of avg's warrant contemporary comparisons between synthetic and biologic avg options. this is especially important as biologic conduits may confer an advantage by virtue of their inherent similarity to the native human vasculature. the overall goal of this project is to compare one and two year patency (functional, primary, primary assisted and secondary), complication rates and re-intervention rates between bca and standard eptfe grafts. the investigators hypothesize that vascular patient who will receive the bca graft will have improved patency as well as lower complication and re-intervention rates compared to the standard eptfe graft.

Eligibility criteria:
inclusion criteria: * patients at least 18 years of age * have end stage renal disease and are undergoing arterio-venous-graft surgery * not eligible to receive an arterio-venous-fistula * provided written informed consent * agreed to return for all required clinical follow up for the study exclusion criteria: * eligible to receive an arterio-venous-fistula * known allergic reaction or history of intolerance to any eptfe or bca components * local infection at avg placement site at the time of surgery * patients with a bleeding disorder or who refuse blood transfusion * patients with an active malignancy * life expectancy less than 1 year * pregnant women or those planning on becoming pregnant for the duration of the study

Keywords: hemodialysis arteriovenous graft polytetrafluoroethylene bovine
retrospective clinical study on adjuvant treatment of coronary heart disease angina pectoris with chinese patent medicine

Conditions: Atherosclerotic Heart Disease With Angina Nos

Summary: a retrospective cohort study was performed in patients with angina pectoris who were treated with oral chinese patent medicine and western medicine.the hospital's medical record management system was used to collect symptoms of angina pectoris, dose and frequency of nitroglycerin use, clinical biochemical test and imaging examination.to explore the clinical efficacy of chinese patent medicine in the treatment of coronary heart disease with angina pectoris, and provide reliable data support for its clinical application.


Eligibility criteria:
inclusion criteria: 1. age 35-75 years old, gender is not limited; 2. admission time is september 1, 2014 - september 1, 1919; 3. patients with coronary heart disease and angina pectoris in the department of cardiology or outpatient department, the diagnosis of angina pectoris meets the diagnostic criteria of western medicine and the standard of tcm syndrome differentiation; 4. patients who met the criteria for drug treatment, the exposed group was treated with traditional chinese medicine combined with western medicine, and the non-exposed group was treated with western medicine alone. exclusion criteria: 1. combined with other heart diseases, neurosis, menopausal syndrome, hyperthyroidism, cervical or vertebral artery type cervical spondylosis, gastro-oesophageal reflux disease or esophageal hiatus hernia may cause chest pain; 2. patients with acute myocardial infarction, heart failure, myocarditis, cardiomyopathy, severe heart valve disease, liver failure or renal failure, malignant tumors and severe metabolic diseases, as well as patients with severe symptoms and uncontrollable angina; 3. pregnant women, lactating women or women of childbearing age who have birth requirements; 4. mental patients, or cognitive dysfunction; 5. the investigator believes that there are other situations that are not suitable for the trial.
evaluation of preoperative use of pregabalin on postoperative analgesia after laparoscopic colorectal surgery

Conditions: Postoperative Pain

Summary: the purpose of this study is to evaluate how effective is the preoperative administration of pregabalin 300mg, to attenuate postoperative pain and opioids consumption after laparoscopic colorectal surgery

laparoscopic colorectal surgery has gained wide acceptance because it is associated with reduced pain, lower morbidity, faster recovery and a shorter hospital stay. however, the optimal postoperative pain management method for patients undergoing laparoscopic colorectal surgery is still under evaluation and most of the recommendations are based on studies performed in open approach procedures. recently, the analgesic effect of pregabalin, as a part of a multimodal analgesia, has been evaluated in many studies. they have shown that pregabalin may have a role in the post operative pain management, as an adjunct. pregabalin is an anticonvulsant and anxiolytic drug, which have a more favorable pharmacokinetic profile from its predecessor gabapentin.

Eligibility criteria:
inclusion criteria: * asa physical status i-iii * patients who undergo laparoscopic colectomy for benign or malignant colorectal disease ( \<τ3 or =t3 tumors without distant metastasis ) exclusion criteria: * contraindication for pneumoperitoneum * contraindication for laparoscopic approach * renal or hepatic insufficiency * alcohol or drugs abuse * history of chronic pain or daily intake of analgesics * psychiatric disorders * inability of patients to use pca pump history of intake of non-steroidal anti-inflammatory drugs the last 24 hours before surgery,use of drainage after the surgery

Keywords: pregabalin laparoscopic colorectal surgery postoperative pain opioid consumption
one vs two weeks treatment for h.pylori eradication a randomized non-inferiority placebo controlled trial

Conditions: Helicobacter Pylori Infection

Summary: 1. to assess the efficacy of the duration of vonoprazan based triple regimen (one versus two weeks), in the eradication of h-pylori among patients attending gastroenterology clinics of karachi, pakistan. 2. to assess the improvement in the quality of life of patients receiving vonoprazan as part of the triple regimen.

introduction: the overall aim of the study is to assess the efficacy of one week of vonoprazan compared to two weeks of vonoprazan in eradicating h-pylori in patients with dyspeptic symptoms. h. pylori is a pathogenic gram-negative spiral bacillus that survives in the acid environment of the stomach. it is a leading cause of chronic gastritis, peptic ulcers, non-ulcer dyspepsia, gastric adenocarcinoma and mucosa-associated lymphoid tissue (malt) lymphoma. it is estimated that up to 50% of the total world population are infected with h. pylori. the prevalence of h. pylori infection is currently rising in the developing world. modified one-week triple therapy (two antibiotics for a week and a potassium-competitive acid blocker for 4-8 weeks) represents the most advanced prescribed regimen for h. pylori infection. with current and widely used therapeutic regimens, (such as two antibiotics and a proton pump inhibitor) there is a significant failure rate for the eradication of microorganism. therefore, interventions that can improve h-pylori eradication along with improving patient's quality of life are highly important. vonoprazan is a potassium-competitive acid blocker, which inhibits the h+/k+ pump in the stomach. unlike proton pump inhibitors, vonoprazan inhibits the pump in a competitive and reversible manner. hence, it is expected to be at least as effective as ppis in the elimination of helicobacter pylori. assessing the duration of vonoprazan based triple therapy is of great concern.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * h pylori infection confirmed by any of the 3 tests c-urea breath test (ubt), , rapid urease test, and stool h pylori antigen. exclusion criteria: * acute gastrointestinal disease (e.g., acute diarrhea) * chronic gastrointestinal disease (e.g., inflammatory bowel disease, celiac disease) * known renal and/or liver failure * no known malignancy * varices bleeding
a prognostic tool for early stage cll

Conditions: Chronic Lymphocytic Leukemia

Summary: the study aims at developing a model for the prediction of time to first treatment in chronic lymphocytic leukemia patients presenting with asymptomatic early stage disease

already existing and coded health-related personal data will be retrospectively collected from the cll databases of the institute of oncology research and of the division of hematology of the university of eastern piedmont. the adjusted association between exposure variables and time to first treatment will be estimated by cox regression. this approach will provide the covariates independently associated with progression free survival that will be utilized in the development of a model to predict time to first treatment. model performance (c-index and net reclassification improvement) in discriminating patients who will eventually be treated vs patients who will not be eventually treated will be compared with that of already existing prognostic model that have been validated to predict overall survival but not time to first treatment in cll (i.e. cll-ipi, mdacc score, barcelona-brno score).

Eligibility criteria:
inclusion criteria: * male or female adults 18 years or older * diagnosis of chronic lymphocytic leukemia * binet a stage at presentation * no treatment need at presentation * availability of the baseline and follow-up annotations exclusion criteria: * none.

Keywords: early stage cll binet a prognosis
prism-genomics-smoking cessation for patients with coronary artery disease undergoing cardiac catheterization or having a heart attack at barnes hospital in st. louis mo

Conditions: Coronary Artery Disease; Smoking Cessation

Summary: it has previously been shown that patients with coronary artery disease may have a harder time quitting smoking if they have a specific genetic profile and that these individuals have a better chance at quitting if they receive nicotine replacement therapy. the investigators hypothesize that determining which individuals with coronary artery disease should receive nicotine replacement therapy based on their genotype may improve the number of individuals who are able to quit smoking.this study randomizes treatment to that determined by the patient's genotype compared to standard, non-genotype-guided, treatment.

in this study, the investigators propose to show the feasibility of incorporating genotype-guided therapy into post-mi smoking cessation therapy and/or smoking cessation therapy in patients with coronary artery disease (cad) using the chrna5 rs16969968 variant as the pilot case. the investigators propose to genotype ½ of prism-genomics patients who are active smokers within 48 hours of admission and to guide their smoking cessation therapy based on chrna5 rs16969968 genotype (a allele carriers will be given pharmacologic therapy and gg homozygotes will be given counseling). the investigators will use the other ½ as controls. the participants will be followed and the investigators will test whether the genotype-guided group has better rates of smoking cessation compared to the control group. this pilot study will lay the foundation for personalized, genotype-guided, post-mi therapy and/or therapy in patients with cad.

Eligibility criteria:
inclusion criteria: * adult * presenting to barnes hospital cardiac catheterization laboratory with coronary artery disease or admitted to barnes hospital within 24 hours of a type 1 myocardial infarction (heart attack) * active smoker at time of presentation to barnes hospital * participating in prism-genomics observational study exclusion criteria: * unable to provide informed consent * unable to answer questions (e.g. intubated) * incarcerated * complications of myocardial infarction (such as shock, hemodynamic instability, life- threatening infection, etc) * women of child-bearing age with positive pregnancy test or who is breast feeding

Keywords: smoking cessation treatment
techniques for abdominoplasty after massive weight loss

Conditions: Skin; Excess

Summary: excess skin on the abdomen is a common problem for many individuals after massive weight loss. the surgical procedure of abdominoplasty is intended to remove excess skin and improve the shape of the torso in abdomen, in order to address issues such as skin fold eczema, difficulties finding clothing, and psychosocial issues. the investigators will conduct a randomized, controlled trial where individuals with excess skin on the abdomen will be randomized to either standard abdominoplasty or abdominoplasty in combination with liposuction. the investigators will examine the rate of complications, and the functional and aesthetical outcomes of the two methods.


Eligibility criteria:
this study is open only to individuals who are residents in sweden and qualify for government-funded, inpatient, non-emergency health care within the stockholm region. inclusion criteria: * bmi \< 30 * stable bmi for \>= 6 months * \>= 24 months since bariatric surgery, if applicable * skin fold of \>= 5 cm * functional and/or psychosocial issues due to abdominal skin excess exclusion criteria: * smoking * ongoing infection

Keywords: randomized controlled trial abdominoplasty massive weight loss plastic surgery liposuction
follow-up of long-term renal function after acute kidney injury in icu

Conditions: Acute Kidney Injuries; Quality of Life; Chronic Kidney Disease; Renal Replacement Therapy

Summary: acute kidney injury (aki) involves poor prognosis in icu patients. the renal prognosis at long term is unknown. the study will determine chronic kidney injury incidence and quality of life, five years after ak during icu stay.

prospective study. all patients who participated elvis study (clinical trials: 00875069) can be enrolled in suria. patients are contacted by telephone. investigator delivery objective and honest information. if patients accepts the study, answers will be collected. collected data are: creatinine serum, two surveys (quality of life and activities of daily living), date of onset of renal replacement therapy.

Eligibility criteria:
inclusion criteria: icu patients included in elvis study, aki requiring renal replacement therapy length of icu stay ≥ 48h exclusion criteria: pregnant or nursing woman's job

Keywords: acute kidney injury quality of life renal replacement therapy intensive care unit